Enrico Derenzini

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Chiara Cattaneo, Luca Arcaini et al. · The Lancet Haematology · 2020 · 554 citations · Full text

Medicine, Hematology, Oncology +16

Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Pier Luigi Zinzani, Gerardo Musuraca, Monica Tani et al. · Journal of Clinical Oncology · 2007 · 280 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

Pier Luigi Zinzani, Filippo Venturini, Vittorio Stefoni et al. · Annals of Oncology · 2009 · 193 citations · Full text

Medicine, Hematology, Oncology +12

Role of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

Pier Luigi Zinzani, Vittorio Stefoni, Monica Tani et al. · Journal of Clinical Oncology · 2009 · 166 citations

Medicine, Nuclear Medicine, Oncology +15

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan Fowler, Felipe Samaniego, Wojciech Jurczak et al. · Journal of Clinical Oncology · 2021 · 161 citations · Full text

Medicine, Oncology, Pharmacology +13